As early as the 1800s, the actions of estrogen have been implicated in the development and progression of breast cancer. The estrogen receptor (ER) was identified in the late 1950s and purified a few years later. However, it was not until the 1980s that the first ER was molecularly cloned, and in the mid 1990s, a second ER was cloned. These two related receptors are now called ER␣ and ER␤, respectively. Since their discovery, much research has focused on identifying alterations within the coding sequence of these receptors in clinical samples. As a result, a large number of naturally occurring splice variants of both ER␣ and ER␤ have been identified in normal epithelium and diseased or cancerous tissues. In contrast, only a few point mutations have been identified in human patient samples from a variety of disease states, including breast cancer, endometrial cancer, and psychiatric diseases. To elucidate the mechanism of action for these variant isoforms or mutant receptors, experimental mutagenesis has been used to analyze the function of distinct amino acid residues in the ERs. This review will focus on ER␣ and ER␤ alterations in breast cancer. (Endocrine Reviews 25: 869 -898, 2004) 
], the colon [reviewed by Di Leo et al. (5) ], and ovarian tissues (6) . It has long been appreciated that estrogenic signaling plays a critical role in the development of breast cancer (7) (8) (9) (10) . As early as the late 1800s, it was recognized that oophorectomy of premenopausal women with metastatic breast cancer caused tumor regression in approximately one third of these patients (9, 10) . In the 1950s, Jensen and Jacobson (11, 12) used tritiumlabeled, 17␤-estradiol to demonstrate that estradiol was specifically retained by estrogen target tissues. The specific tissue targeting of radiolabeled estradiol led them to hypothesize that a receptor must exist for this molecule. In the next decade, an estrogen receptor (ER) was identified by Toft and Gorski (13) and isolated from several mammalian species, including rat and human (14 -16) . However, it was not until the mid 1980s that the first ER, now called ER␣, was cloned by two groups of investigators (17) (18) (19) (20) . In the mid 1990s, a second ER, called ER␤, was identified in a library scan of rat (21) and subsequently cloned from several species including the mouse, human, and fish (21-23). At first, a human ER␤ with 477 amino acids was reported (23). A few months later, Enmark et al. (24) reported the identification of an ER␤ mRNA species with a size of 485 amino acids, and it was hypothesized to reflect full-length ER␤. The following year, Ogawa et al. (25) reported the cloning of an additional ER␤ species consisting of 530 amino acids, which is now considered to represent full-length ER␤. A few months later, Moore et al. (26) also identified the same 530-amino acid sequence as the full-length ER␤, as well as various isoforms. As has been extensively shown for ER␣, ER␤ expression has also been associated with cancers of the breast (27-30), colon (31, 32), and ovarian tissues (6, 33) . Additionally, studies with ER␣ and ER␤ knockout (KO) mice have revealed a role for ER signaling in bone formation, male and female sexual maturation, fertility, cardiovascular and angiogenesis effects, and behavior (34 -57). These effects of ER␣ and ER␤ KOs are completely reviewed by Couse and Korach (58) and will not be covered here. Other topics, such as the role of the two ERs in human disease (59 -61), ER structure and function (62), ER interaction with other cellular signaling molecules (63, 64), ER coregulators (62, 65, 66), and the pharmacology of selective estrogen receptor modulators (SERMs) (67, 68), are also extensively reviewed elsewhere, and hence will only be modestly reviewed here for the purpose of background information. This review will instead focus on the genetic alterations that have been identified in the human ERs, including sequence mutations and RNA splice variants.
II. ER Structure
ER␣ and ER␤ are separate genes, and do not represent splice variants. Accordingly, ER␣ is found on chromosome 6q, whereas ER␤ is localized to chromosome 14q (24, 69, 70). To fully understand the consequences of specific ER mutations or variants, one must first be familiar with the functional domains of the two ERs. Figure 1 shows the six structural domains (termed domains A-F) of ER␣ (71), and Fig. 2 presents the ER␤ structural domains as defined by Ogawa et al. (25) . There is a predicted 96% homology in the DNA binding domain (C), and a 53% homology between the E/F domains, but the A, B, and hinge (D) domains are not well conserved between ER␣ and ER␤ as reported by Ogawa et al. (25) . In addition to their structural domains, the ERs contain defined functional domains. The transactivation domain termed activation function (AF)-1 is contained within the amino-terminal A and B domains and contains ligand-independent activation function (72-75). In addition, the A/B region contains a coregulatory domain, which binds various ER coactivators and corepressors that modulate ER-mediated transcriptional activity. The C domain is composed of two zinc finger motifs and encodes the DNA binding domain that is responsible for binding to specific estrogen response elements (EREs) within the promoters of estrogen-responsive genes (72, 76, 77) . The ER dimerization domain is discontinuous, is split between the C and E domains, and is required for the ERs to dimerize, allowing binding to the entire ERE site (72). The structural D domain contains the hinge region, part of the ligand-dependent, transactivation domain AF-2a and a portion of the ER nuclear localization signal (78, 79). The carboxy-terminal E and F regions contain the ligand binding domain and the ligand-dependent AF-2 transactivation domain (78). Finally, as previously mentioned, this carboxy-terminal region is also involved in receptor dimerization, the binding of coregulatory proteins, and the binding of chaperone proteins, such as heat shock proteins 70 and 90 (80, 81).
Both ER␣ and ER␤ bind to specific DNA sequences called EREs that are inverted palindromic repeats (5Ј-GGTCAnnnTGACC-3Ј), where n ϭ any nucleotide (76, 82, 83). Additionally, sequences flanking the EREs also play a role in ER-DNA binding affinity (83-90). When ER␣ binds to an ERE, it induces a bend of the DNA toward the major groove, allowing complex interactions between different components of the transcription factor complex (91-96). These include components of the basal transcription factor complex The ligand-independent AF-1 domain can be activated by cAMP, dopamine, vanadate, and growth factors such as epidermal growth factor (EGF) and IGF (77, 101-106). The AF-1 domain demonstrates ligand-independent activation that is closely related to its phosphorylation status (102, 105, 107). The A/B region also contains a coregulator binding domain, where coactivators such as p68 and steroid receptor coactivator (SRC)-1 and corepressors such as Ssn3 bind and modulate ER-mediated transcriptional activity (108 -112). AF-2 and AF-2a demonstrate ligand-dependent activity (72, 73, 77, 78, 113). AF-2 also contains coregulator binding sites for the coactivators SRC-1, -2, -3 and CREB binding protein (CBP), as well as the corepressors thyroid hormone receptor interacting protein (TRIP1) and repressor of estrogen activity (REA), to name only a few (108, 110, 114 -120) . Mutations in these AF-1 and AF-2 functional domains can alter ER signaling by activating or inactivating the protein or by altering the binding of coregulator proteins and, indirectly, modulating ER signaling.
The crystal structure of ER␣, ER␤, and several other nuclear receptors bound to agonists has demonstrated that ligand binding to the carboxy-terminal hydrophobic pocket induces helix 12 to position itself over the pocket (121) (122) (123) (124) (125) . This repositioning stabilizes helix 12, allowing it to recruit transcriptional coactivators required for full agonist action (126, 127) . When ER is bound to partial agonists or antagonists such as tamoxifen, Faslodex, or raloxifene, the "bulky" side chain of the compound prevents helix 12 from adopting the agonist bound position over the pocket, thus antagonizing coactivator binding to the ERs (124, 128 -132) . Compounds without bulky side chains, such as genestein or THC (5,11-cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol) inhibit full ER activation by stabilizing nonproductive conformations of the ligand-binding pocket (128, 129) . The mechanism of tamoxifen-mediated repression has been well studied and has demonstrated that tamoxifen-bound ER␣ can recruit corepressors such as nuclear receptor corepressor (NCoR) and silencing mediator of retinoid and thyroid receptor (SMRT) (133) (134) (135) (136) (137) (138) . In contrast, ER␤ has been shown to recruit these corepressors in the presence of agonists, but not antagonists (139) . Furthermore, reduced expression of NCoR and SMRT has been correlated with tamoxifen resistance in breast tumors (134 -136, 138, 140) , demonstrating the importance of putative helix 12 mutations. This review will focus on ER mutations that lead to alterations within the protein sequence, particularly those that alter AF-1 or AF-2 function. The many ER mRNA splice variants that have been identified, which predict variant forms of the ER proteins, will also be discussed.
III. Roles of ER␣ and ER␤
With the relatively recent discovery of ER␤, the separate cellular roles for ER␣ and ER␤ are just now being elucidated. ER␣ and ER␤ have been demonstrated to form heterodimers, as well as homodimers, further complicating their individual and/or combined function within a cell. Although both receptors bind estrogen with similar affinities, ER␤ appears to have a stronger affinity for phytoestrogens (141) (142) (143) . ER␤ also exhibits reduced transactivation in most cells when directly compared with ER␣, and this is likely due to the weaker AF-1 activity of ER␤ (144 -146) . In contrast, AF-2 activity is similar for both ER␣ and ER␤, depending on the cell-type (147, 148) . These receptors display differential ligand-induced activity; therefore, it is predicted that they could also differentially regulate transactivation of heterologous promoters (149) . Paech et al. (149) have shown that estrogens up-regulate ER␣ activating protein (AP)-1 activity, whereas ER␤ AP-1 activity is reduced. In contrast, the antiestrogens tamoxifen, raloxifene, and ICI 164,384 all increase AP-1 activity of both ER␣ and ER␤. Furthermore, serotonin-1A has been shown to be specifically up-regulated through nuclear factor-B (NF-B) induced by ER␣ signaling, but not ER␤, demonstrating receptor gene specificity (150) . When MDA-MB-231 cells were engineered to overexpress either ER␣ or ER␤, both ER␣ and ER␤ decreased in vitro invasion (151); however, ER␣-overexpressing cells reduced proliferation in a ligand-dependent manner, whereas ER␤ was able to repress proliferation in a ligand-independent manner, thus demonstrating divergent roles for these receptors. Although ER␣ and ER␤ share similar ligand specificities and some signaling actions, they appear to respond to ligands in a receptor-specific manner.
Work with ER KO mice has demonstrated that these receptors are not dependent on or under the control of each other, because mice deficient in one receptor are not lacking in the other (152) (153) (154) (155) (156) . Mammary glands of ER␣ KO mice have normal embryonic and fetal development, but these glands never develop beyond the newborn stage (41). In contrast, mammary glands of ER␤ KO mice develop normally with ductal structures that fill the fatpad but exhibit reduced side branching in nulliparous glands (37, 157), thus demonstrating that ER␣ is the predominant receptor involved in mammary gland development. It should be noted that, in a number of studies, ER␣ KO mice, although lacking the full-length ER␣, express shorter isoforms of ER␣ mRNA and protein with some residual signaling activity (38, 158, 159) . Examination of mammary glands from pregnant and lactating ER␤ KO mice has revealed that ER␤ expression is required for normal lobuloalveolar development (157) . Additionally, analysis of tight junction proteins, gap junction proteins, smooth muscle actin, and Ki67 expression all suggested that ER␤ KO mice have less well-differentiated mammary glands compared with wild-type mice (157) . Because ER␣ KO mice do not develop normal adult mammary glands, it will be necessary to develop conditional KOs to more adequately model human breast cancer development and progression and to fully delineate hormone action during development.
Because ER␣ KO mice have significantly impaired mammary gland development, it is perhaps not surprising that these mice would be resistant to 7,12-dimethyl benz[a]-anthracene (DMBA)-induced mammary tumors (160) . Interestingly, when mice lacking ER␣ expression were crossed with transgenic mice overexpressing the mouse mammary tumor virus-Wnt-1 oncogene or the mouse mammary tumor virus-Her2/neu oncogene, mammary tumors did indeed develop (161, 162) ; however, tumor development was delayed when compared with mice expressing wild-type receptor (161, 162) . Collectively, these data demonstrate that although ER␣ can contribute to mammary tumorigenesis, it is not absolutely required.
IV. ERs in Human Breast Cancer
ER signaling is known to be necessary for the proper development and maturation of the mammary gland by stimulating DNA synthesis and promoting bud formation (163) (164) (165) (166) . It is estimated that only 7-10% of the epithelial cells in the normal human breast express ER␣, and it has been shown that this expression fluctuates with the menstrual cycle (167) (168) (169) (170) (171) (172) (173) . Although only a small percentage of the cells in the normal breast express ER␣, these are not the same cells as those that are proliferating (174 -176) . In contrast, ER␤ expression is relatively high in the normal breast, with 80 -85% of the cells expressing ER␤, which is again inversely correlated with cellular proliferation (59, 177). In contrast, ER␤ expression does not appear to change during the menstrual cycle (178 -180) . Although ER signaling is required for normal mammary gland development, it has been hypothesized that aberrant signaling could lead to abnormal cellular proliferation and survival, potentially participating in the development and progression of breast cancer. Similar to invasive breast cancer, low-grade ductal carcinoma in situ (DCIS) has been demonstrated to have 75% of the cells expressing high levels of ER␣, but high-grade DCIS has approximately 30% of the cells expressing low levels of ER␣ (181) (182) (183) (184) (185) (186) (187) (188) (189) (190) (191) (192) (193) . Additionally, it has been shown that DCIS lesions have reduced ER␤ expression compared with normal epithelium, with high-grade DCIS showing the most significant reduction in ER␤ levels (177, 178) . Although reduced, invasive breast carcinomas show high levels of ER␣ and ER␤ with approximately two thirds of the tumors staining positive by immunohistochemistry (28, 180, 194 -196) . To date, few large studies have been performed analyzing ER␤ protein expression in normal breast, early lesions, and invasive cancers. Two recent studies, although having varying cutoffs, have demonstrated reduced intralesional ER␤ expression in DCIS when compared with normal epithelium (197, 198) . Additionally, these studies demonstrated a further loss of ER␤ expression from DCIS to invasive cancer. One study demonstrated a 21% reduction in tumors expressing ER␤ (194) , whereas a second study demonstrated a reduction in intralesional ER␤ expression and not a reduced number of invasive breast cancers expressing ER␤ (198) . Interestingly, when primary tumors and matched lymph node metastases where compared, there was not a significant reduction in lymph node metastases staining positive for ER␤ expression (197) . Although it has been much hypothesized that ER␤ has tumor-suppressor-like activity in the breast (199) , ER␤ would have to be unique among tumor suppressors if expressed in over 75% of invasive lesions (178) . Undeniably, much more work is required to understand this paradox. Collectively, these data indicate that although ER␤ levels may vary, ER␣ expression levels rise during tumor progression.
The potential role of ER␤ in breast cancer progression is highly controversial. Many studies have suggested that ER␤ expression is a favorable prognostic indicator, whereas additional studies have suggested that ER␤ expression is associated with known factors of poor clinical outcome. Basically, two types of prognostic studies have been performed to date, those evaluating RNA levels, and those evaluating protein expression. It is interesting to note that many of the studies indicating that ER␤ is a poor prognostic indicator have evaluated only the RNA levels by quantitative or semiquantitative PCR techniques. Many of these RNA-based studies have correlated ER␤ expression with markers of a poor prognosis, such as EGF receptor expression and high tumor grade, and an inverse correlation between ER␤ expression and progesterone receptor (PR) status (28, 30, 200, 201) . However, a few studies evaluating RNA have demonstrated that ER␤ expression is reduced in breast cancer compared with normal epithelium, and that it is inversely correlated with proliferation (evaluated by measuring Ki67 levels) (177, 202) , thereby suggesting that ER␤ expression is a favorable prognostic indicator. However, PCR analysis of RNA levels from tumor samples will also measure ER␤ mRNA in the "normal" surrounding cells, stroma, and contaminating immune cells present in homogenized tissues. Additionally, many PCR primers may also amplify alternatively spliced RNA variants, thereby increasing the falsepositive rate or perhaps skewing results toward higher expression levels. Thus, protein analyses would more precisely measure ER␤ expression levels in clinical samples.
Studies evaluating ER␤ protein expression appear to be much less contradictory. Direct protein analyses generally suggest that ER␤ protein expression is a favorable prognostic indicator, correlating with known biomarkers such as low histological grade, ER␣ and PR expression, longer diseasefree survival, and response to tamoxifen (180, (195) (196) (197) (203) (204) (205) . Although these studies do not always agree on the specific associations with known prognostic indicators, they do generally agree that similar to ER␣, ER␤ expression is a favorable prognostic indicator. A few protein-based studies have suggested that ER␤ expression is associated with high proliferation (Ki67 expression) and high tumor grade (206, 207) . However, these studies have varying cut-off points for being classified as ER␤-positive, requiring 20 -25% of the cells staining positive for ER␤. Furthermore, these later studies examined small tumor subsets. Mann et al. (205) , have demonstrated that tumors with as little as 10% of the cells expressing ER␤ have a more favorable response to tamoxifen, thus suggesting that only 10% positive cells may be a reasonable cut-off point for classification of ER␤ status in tumors, as has been adopted for ER␣ and tamoxifen responses (208) . However, these methods give an estimate of the percentage of positive cells, but they do not account for expression levels in individual cells. The Allred score, used in several studies, measures both the percentage positive and the relative intensity, thus providing a semiquantitative method of ER protein expression (209) . It is clear that the role of ER␤ in breast carcinogenesis has not been fully elucidated; however, direct protein analysis strongly suggests that ER␤ is an indicator of a more favorable clinical outcome. A uniformly adopted classification of ER␤ expression will be required to reconcile these issues and may help to clarify the potential role of ER␤ in breast cancer progression.
It has also been suggested that it is not necessarily the individual level of ER␣ or ER␤ that is clinically relevant, but the ratio of ER␣:ER␤ that may change and impact tumorigenesis. In support of this hypothesis, it has been shown that ER-positive breast cancer has a mean higher ER␣:ER␤ ratio when compared with the normal tissue; in contrast, estrogenindependent, ER-negative cancer exhibits a low ER␣:ER␤ ratio (201, 210) . Further complicating this hypothesis, however, is the existence of ER␣ and ER␤ splice variants that may contribute to measurements and result in an overestimation of mRNA or protein expression. It is evident that the interplay between ER␣ and ER␤ could be complicated; data exist that both may have roles within normal breast epithelial cells and that up-regulation or down-regulation of one receptor could potentially upset a physiological balance. Thus, although a definitive role for ER␤ in breast carcinogenesis has not yet been demonstrated, it can be concluded that ER␣ appears to play the dominant role in the breast.
V. Splicing and Genetic Alterations of ER␣

A. Alternative exons in the 5ЈUTR
The majority of efforts to understand ER action have focused on its functional domains and protein-protein interactions. Over the past several years, many investigators have separately identified and named as many as eight upstream untranslated ER␣ exons (69, [211] [212] [213] [214] [215] [216] . Because these exons have been identified and differently named, this review will use the nomenclature suggested by Flouriot et al. (216) , as modified by Kos et al. (217) and shown in Fig. 1A . ER␣ exon 1, as defined by Green et al. (18) , contains an acceptor splice site at ϩ163, permitting the splicing of several different exons encoding various 5Ј untranslated regions (UTRs). To date, at least seven different promoters have been described, allowing for a relative amount of tissue specificity [for a complete review, see Kos et al. (217) ]. The most common promoter found expressed in tissues and cell lines is encoded in exon 1 and is termed promoter A. What is now called promoter C was first described in 1991 (214) , and a longer version of promoter C was described a couple of years later (212, 214) . In subsequent years, exons A-E were described. These various upstream exons have been shown to affect reporter gene expression levels (218) . Numerous AUG start codons are found in these various 5ЈUTRs and are thought to inhibit the scanning ribosomes from reaching the start codon responsible for full-length ER␣ translation, thus reducing ER␣ protein expression (218) . The tissue specificity of these various 5ЈUTR promoters has been examined (216, 219) . It was found that the promoters within 2-kb pairs of the acceptor splice site, namely promoters A, B, and C, are predominately used in cell lines and tissues expressing relatively high levels of ER␣, whereas the more distal promoters, named E and F, are found in tissues where ER␣ is less abundant, such as the liver and osteoblasts (219) . Although these promoters demonstrate some tissue-specific expression, Brand et al. (211) have reported the identification of two new exons, called T1 and T2, that are expressed predominantly in the testis and the epididymis. Because these different promoters can indeed control tissue-specific expression, as well as ER␣ levels, the inappropriate splicing of these promoters may affect the expression and ER␣ signaling activities.
B. mRNA splice variants
ER␣ splice variants have been detected in a number of different normal tissues, including the breast, endometrium, and pituitary tissues, as well as smooth muscle cells and peripheral blood mononuclear cells (220 -224) . Additionally, ER␣ mRNA splice variants have been detected in various tumor types including breast cancer, endometrial carcinoma, prolactinoma, systemic lupus erythematosus, and meningiomas, to name a few (see Table 1 and references therein). In the vast majority of cases, wild-type ER␣ is coexpressed along with variant ER␣ mRNAs (225) (226) (227) . Although many of these variants have been predominately detected in diseased tissues, a number of studies have been unable to demonstrate differences in the expression levels, or individual patterns of mRNA splice variants when comparing normal controls from unaffected patients to diseased tissues, suggesting that these variants may also play a role in normal physiological processes (220, 221) . A large number of splice variants have been reported; therefore, only the most common RNA splice variants will be discussed herein. Unfortunately, the study of predicted proteins of these RNA variants is rare, but we will include a discussion of protein isoforms when appropriate.
ER␣ exon 2 deletion (⌬2).
This deletion variant potentially encodes a truncated protein containing only the A and B domains of ER␣ (Fig. 1) where the ligand-independent activation domain AF-1 is located. Because ⌬2 is missing the DNA binding domain, it is not surprising that it lacks any transcriptional activity (228) . Furthermore, it lacks the dimerization domain and thus is unable to affect wild-type ER signaling (228) . The ⌬2 variant would also not be predicted to exhibit significant transcriptional activities, because it is a carboxy-terminal truncated protein lacking many protein in- teraction domains. However, it has been shown to repress Fos-mediated transcription in HeLa cells (229) . In addition, experiments using tamoxifen-resistant and -sensitive MCF-7 cell lines did not find any differences in expression of this splice variant, suggesting that ⌬2 does not play a role in tamoxifen resistance (230) . Because it is known that the AF-1 domain alone can be involved in ER crosstalk with other signaling pathways and affect growth-factor mediated ER activation, this mechanism may be involved in any observed repression resulting from expression of ⌬2. The ⌬2 variant has been detected in a number of tissues. It is interesting to note that in diseases such as breast cancer and systemic lupus erythematosus, where this variant has been identified in both the normal and diseased tissue, no associations were found between relative expression and the particular disease state (221, 231) . Additionally, ⌬2 has also been identified in normal endometrium, but not in hyperplastic endometrium or endometrial adenocarcinoma (232, 233) . However, this ER variant was not found in the normal pituitary but has been identified in prolactinoma, a tumor arising from the pituitary (222) . These data suggest that the exon 2 deleted ER␣ splice variant may be regulated in a tissue-specific manner, but probably does not play a significant role in tumorigenesis.
ER␣ exon 3 deletion (⌬3).
The ER␣ ⌬3 splice variant results in an in-frame shift that is missing part of the DNA binding domain. This deletion results in a protein with dominantnegative activity that is able to suppress estrogen-induced transcriptional activity (228, 234) . Because this variant is unable to bind DNA, its ability to act as a dominant-negative isoform most likely occurs through dimerization with wildtype ER␣ (228) . Stable transfection of ER␣ ⌬3 into the ER␣-positive MCF-7 breast cancer cell line resulted in an 80% reduction in invasion using a chick embryo chorioallantoic membrane assay (235) . Treatment of these ⌬3-expressing cells with estrogen also reduced soft-agar colony-forming ability to below basal levels (235) . Because ⌬3 is able to inhibit estrogen-induced transcriptional activity, its expression could potentially affect ER␣ signaling.
The ⌬3 variant has been detected in prolactinoma, endometrial hyperplasia, and breast cancer (222, 225, 233) . Comparison of the ER␣ ⌬3:wild-type ER␣ ratios demonstrated that normal breast tissues have a median ratio of 3.4, whereas breast cancers, due to ⌬3 down-regulation, have a median ratio of 0.11 (235) . Additionally, ⌬3 has been detected in the majority of ER-positive, PR-negative breast tumors (225) , suggesting a role in the discordant receptor phenotype. ⌬3 was not detected in normal pituitary, normal endometrium, or endometrial carcinoma (222, 233) . This variant was also found in 19 of 21 endometrial hyperplasias but was not detected in 29 endometrial carcinomas (233) . The dominant negative activity of ⌬3 may serve to reduce normal estrogenic signaling, thereby influencing tumor progression and growth. It is interesting to note the tissue-type manner in which this variant has been found. Although prolactinomas and endometrial hyperplasias expressed ⌬3, endometrial carcinomas did not; and furthermore, normal breast tissues have significantly reduced levels, prompting the question does ⌬3 have contrasting roles in alternatively promoting or protecting from tumorigenesis in a tissue-type dependent manner? In addition, ER␣ ⌬3 expression is reduced by over 30-fold in breast cancer when compared with normal breast epithelium; and because ER␣ ⌬3 has dominant negative activity [requiring significantly higher levels of ⌬3 for dominant negative activity (236) ], the loss of ER␣ ⌬3 may "relieve" normal physiological repression of ER␣ signaling. To our knowledge, no antibodies specific for ⌬3 exist to test this hypothesis.
ER␣ exon 4 deletion (⌬4).
Deletion of ER␣ exon 4 results in an in-frame deletion that encodes a protein lacking a nuclear localization signal, the AF-2a activation domain, and part of the hormone binding domain. The resulting variant isoform is unable to bind hormone or DNA, and therefore has no basal or estrogen-induced transcriptional activity (237) . Additionally, this alternately spliced ER␣ isoform does not appear to interfere with wild-type ER␣ activity (237) . Although these data suggest that expression of this variant would be of no significant consequence to a cell, its RNA expression has been associated with biomarkers of a more favorable clinical outcome for breast cancer, such as low grade and high PR levels (225, 238) . In addition, ⌬4 RNA is more common in PR-positive breast cancer (225, 238) . When endometrial hyperplasia and adenocarcinomas were examined for the presence ER␣ ⌬4, it was found in 17 of 21 hyperplasias but was absent in 29 adenocarcinoma samples (233) . It is not understood how ⌬4 expression could associate with markers of a more favorable clinical outcome for breast cancer; because it has no appreciable binding or transcriptional activity, larger studies will be required to demonstrate that ⌬4 expression is indeed significantly associated with a more favorable clinical outcome for either breast or endometrial carcinoma?
ER␣ exon 5 deletion (⌬5).
We first identified the ER␣ exon 5 deletion isoform that results in the introduction of a stop codon within the ligand binding domain (239) . Although the resulting 40-kDa protein lacks most of the ligand binding domain, it retains AF-1 activity and DNA binding ability (239) . The ⌬5 retains its ligand-independent transactivation domain AF-1; therefore, it is not surprising that the encoded protein is constitutively active in a yeast transactivation assay or transfected into some breast cancer cell lines (239 -241) , although not all cell lines (242) . Many studies have attempted to correlate expression of the ⌬5 splice variant with tamoxifen resistance in clinical samples. One study by Madsen et al. (230) found similar levels of ⌬5 mRNA in both tamoxifenresistant and tamoxifen-sensitive MCF-7 cells. In support of this in vitro result, two separate studies reported by Daffada et al. (243) and Zhang et al. (225) examined 120 and 109 primary breast tumors, respectively, and did not find any correlation between ⌬5 mRNA expression levels and the tamoxifen-resistant phenotype (225, 243) . In contrast, several in vitro studies in our laboratory have shown that overexpression of ER␣ ⌬5 in MCF-7 cells confers relative tamoxifen resistance (240, 244) . In these studies, we used exogenously expressed ⌬5 in MCF-7 cells, whereas the studies by Madsen et al. looked for levels of this splice variant in acquired tamoxifen-resistant cells. These data suggest that although ⌬5 is able to confer tamoxifen resistance in vitro, it is probably not a major mechanism of de novo or acquired tamoxifen resistance in invasive breast cancer.
ER␣ ⌬5 was first identified in a small number of ERnegative, but PR-positive breast cancers, and these tumors tend to have higher expression levels of ⌬5 (239, 245) relative to wild-type ER␣. In addition to primary breast cancer, ⌬5 has also been found in normal breast tissue, and is expressed at increased levels in breast cancer metastases (225, 231, 246, 247) . Interestingly, this variant has not been found in breast hyperplasias but has been found at reduced levels in normal tissue adjacent to breast cancer (231, 240, 248) . Regardless of these correlative findings, ⌬5 levels have not associated with known clinical prognostic indicators such as ER or PR status, tumor size, or S-phase fraction (225) . Thus, although expression of ER␣ ⌬5 mRNA is elevated in breast cancers compared with normal tissues, collectively, these data do not support a dominant role for ER␣ ⌬5 in breast tumorigenesis, and convincing evidence for protein expression in patient samples has not been presented.
In addition to breast cancer, other tumor types exhibit expression of ⌬5; pituitary tumors, but not normal pituitary, express ⌬5 (222). In addition, this is the only ER␣ splice variant whose expression has been detected at a significantly increased level in endometrial carcinomas, compared with endometrial hyperplasias (233) . Peripheral blood mononuclear cells in patients with systemic lupus erythematosus also express either wild-type ER␣ or the ⌬5 variant, but not both isoforms (249, 250) . Thus, at present one can conclude that although ⌬5 does not appear to play a significant role in breast tumorigenesis, there may be an as yet undefined role for ⌬5 in other tumor types.
ER␣ exon 6 deletion (⌬6).
There have been few reports of an ER␣ exon 6 deletion variant. Poola and Speirs (251), using RT-PCR assays, first found this variant in one of 35 normal breast samples, but in seven of 38 clinical breast cancer specimens. Using this same technique, ⌬6 has been detected in several ER-positive breast cancer cell lines, including MCF-7 and T47D (252) (see Table 1 for a complete listing). The exon 6 region encodes a portion of the hormone binding and dimerization domains, and it has been demonstrated using experimental mutagenesis (see Table 3 ) that many important functional amino acids reside within this exon. Although this region is rarely deleted, it is commonly duplicated (Table 1) , and three naturally occurring mutations lie within this exon (Table 2 ). These data are suggestive of an important role for exon 6 in ER␣ signaling, and may help to explain why this particular exon is rarely deleted in vivo.
ER␣ exon 7 deletion (⌬7).
The ER␣ splice variant with a deleted exon 7, first identified by us, is the most frequently observed variant in breast cancer, regardless of ER status of the tumor (225, 253) . It potentially encodes a protein lacking the AF-2 domain and a portion of the hormone binding domain. Although this variant is not transcriptionally active, it has been demonstrated to act as a potent dominantnegative isoform for ER␣ and ER␤ (254, 255) . In addition to breast cancer, this variant has been found at a high frequency in meningiomas, endometrial hyperplasias, and moderate-to well-differentiated endometrial adenocarcinomas (233, 256) . Interestingly, only 20% of poorly differentiated endometrial adenocarcinomas were found to express the ⌬7 variant (233) . This variant has also been identified in prostate cancer cell lines, systemic lupus erythematosus, and peripheral blood mononuclear cells (221, 257) . We have shown that whereas approximately 30% of total ER␣ is the ⌬7 splice variant, only two of 23 tumors expressed ⌬7 at the protein level (254) . Additionally, despite high levels of mRNA, Madsen et al. (230) were unable to demonstrate ⌬7 protein expression in MCF-7 sublines. Although this ER␣ variant is commonly expressed in breast cancer, it also does not appear to play a significant role in tamoxifen resistance (225, 230) . To date, only RT-PCR analysis has been used to demonstrate high levels of ⌬7 mRNA expression, and protein-based analyses have not confirmed these RNA-based results. Although ⌬7 
ER␣ insertion and exon duplications.
In contrast to the lack of single exon 6 deletion variants, a number of the ER␣ variants with multiple exon duplications or multi base-pair insertions involve exon 6; 7.5% of breast cancers examined (n ϭ 212) demonstrate a duplication of exon 6 (226) . This duplication results in a truncation immediately after the duplicated exon, leading to a 50-kDa protein that lacks the AF-2 and dimerization domains (226) . A duplication of both exons 6 and 7 results in an 80-kDa protein that has lost the ability to bind ligands, such as estrogen or tamoxifen (258 -261) . This duplication was originally identified in an estrogen-independent MCF-7 subline and is the result of a genomic rearrangement, rather than alternative RNA splicing (258) . A 69-nucleotide insertion between exons 5 and 6 has also been identified in three of 212 breast cancer tumor specimens analyzed (226) . This 69-nucleotide insertion results from a point mutation in the intron creating a consensus splice donor site (262) . Because a consensus splice acceptor site is located 5Ј to the 69-nucleotide sequence, this short intron sequence is recognized as an exon (262) . Karnik et al. (263) examined tamoxifen-resistant breast cancers for mutations and identified a 42-bp insertion within exon 6. As with the other major ER␣ splice variants, the individual importance of ER␣ exon 6 remains unclear, because it is rarely deleted and is a common site for duplications, suggesting that exon 6 may play an important role in the general function of ER␣.
C. ER␣ experimental splice variants
The human ER␣ (HE) series of experimental splice variants are widely used both as experimental variants and as backbone plasmids for additional mutational analysis. Originally, 14 deletion and/or truncation mutants were made and called HE1-HE14, and they helped to identify the functional domains of ER␣ (264) . In subsequent years, many additional variants with single or multiple deletions and N-terminal and C-terminal truncations have been made; however, these are too numerous to mention, so they will not be discussed here (73, 75, 81, 265) . Figure 3 shows the deleted portions of the ER␣ protein in the original HE series mutants (264) . HE5-HE9 mutants were unable to bind estradiol, indicating that the hormone binding domain was within amino acids 301-552 (264) . Deletions that altered domain C (HE3, HE4, or HE11) or domain D (HE12) reduced nuclear association and ERE binding (81, 264). These original mutants as well as the continued series of deletions and truncations have been valuable tools in mapping the functional domains of ER␣.
D. mRNA splice variants summary
Zhang et al. (225) examined the mRNA ratios of wild-type ER␣ to a number of exon deletion variants in 109 breast cancer specimens and found that the expression of wild-type ER␣ was greater than the expression of any of the deletion variants in the majority of cases. In all samples, ER␣ ⌬2 expression was less than wild-type ER␣; ER␣ ⌬3 and wildtype ER␣ were expressed at similar levels in 7% of the cases; and higher levels of ⌬3 were found in 14% of the cases (225) . Wild-type ER␣ was expressed at similar levels as ⌬4 and ⌬5 in 16 and 6% of the cases, respectively, and 12% of the cases had increased ⌬4 or ⌬5 (225). ER␣ ⌬7 was expressed at higher levels in only 9% of the cases, but the expression of ⌬7 equaled that of wild-type ER␣ in about 20% of the breast cancers examined. These data demonstrate that although a large number of tumor specimens may express variant ER␣, wild-type ER␣ is the predominant isoform in most tumors. One consideration is whether these splice variants are expressed at a level that could significantly affect ER action in cells.
Compared with the number of mRNA splice variants, relatively few variant protein isoforms have been examined, in part, due to the lack of antibodies with the ability to detect specific deleted exons. Although PCR and sequencing can determine the ER␣ exact deletion and/or insertion, antibodies reacting with a different size band only give the relative size and the epitope, but not the isoform identity. A number of groups have compared amino-terminal, carboxy-terminal, and exon-specific antibodies in immunohistochemical studies. These studies have demonstrated that the pattern of immunohistochemical staining is not always identical for antibodies reacting with different epitopes (266, 267) . Typically, the amino-terminal signal was found to be stronger than the carboxy-terminal signal, suggesting the presence of truncated variants of ER␣ in clinical samples (266, 268) . Western blot analysis of tumor samples has demonstrated a number of different ER␣ isoforms, corresponding to the predicted protein sizes of specific molecular weight forms of mRNA splice variants (245, 246, 269) . For instance, Desai et al. (246) developed an ER␣ ⌬5-specific antibody and demonstrated a positive correlation between ER␣ ⌬5 expression and diseasefree survival in breast cancer patients. Thus, whereas the number of detected alternatively spliced ER␣ mRNAs is large, the number of variant isoforms that appear to be stably translated in vivo is infrequent.
In vitro analysis of ER␣ variant isoforms has demonstrated a range of activities, including constitutive activation and dominant negative phenotypes. Theoretically, a small amount of a constitutively active isoform could significantly up-regulate total ER␣ activity. In contrast, numerous studies have demonstrated that significantly higher amounts of dominant negative receptor are required to obtain significant inhibition of wild-type ER␣ signaling. For instance, dosedependent inhibition of ER␣ transactivation has been demonstrated with a number of different dominant negative constructs, including ER␣ ⌬3 and ER␣ ⌬7 as well as ER␤ ⌬5 (236, 254, 270) . Erenburg et al. (235) , using transient transfection assays, demonstrated that 10 times more ER␣ ⌬3 is required to obtain an 80% inhibition of estrogen-induced ER␣ transactivation in HeLa cells. MCF-7 cells stably expressing ER␣ ⌬3 at varying levels showed a dose-dependent reduction in pS2 mRNA, with the greatest reduction in cells expressing higher levels of variant than wild-type protein. These in vitro studies support the concept that significantly higher amounts of dominant negative ER, compared with wild-type receptor, are required to inhibit ER function. Because it has been shown that relatively few tumors demonstrate variant expression levels higher than wild-type ER␣ (225) , thus is the expression of variant ER␣ isoforms really playing a significant role in this small subset of tumors? Although 10 times more DNA was required to reduce transactivation in transient transfection assays, stable transfection and expression of similar or even slightly less ER␣ ⌬3 did significantly reduce anchorage-dependent growth, soft-agar colonyforming ability, and in vitro invasion of MCF-7 breast cancer cells (235) . This later result could suggest that although low level dominant negative inhibition may not dramatically affect transactivation, it may significantly impair the ability of a cell to survive and grow, at least in vitro.
E. Natural mutations of ER␣ identified in human tissue samples
Several groups have reported single mutations within the ER␣ sequence, however many of these are silent mutations or polymorphisms that do not affect the protein sequence. Some of the identified mutations do result in an altered ER␣ protein sequence and have been detected in a variety of tissues and diseases, including breast cancer and its metastases, endometrial cancer, and physiological disorders ( Table  2) . Only those ER␣ mutations that have been identified in breast cancers will be discussed here.
Although two thirds of all breast cancers express ER␣, mutations within the ER␣ sequence are relatively rare. One study found that mutations occur in only 1% of primary tumors (271) . It has been suggested that the mutation frequency may be higher in metastatic breast tumors, and some of these have been correlated with tamoxifen resistance and estrogen independence (263, 272) . For instance, recent studies have demonstrated increased mutation rates in metastatic breast lesions (272) . We have identified a somatic mutation at nucleotide 908 of ER␣ in 34% of hyperplastic breast tissues (273) . This later study used newer, more sensitive detection techniques, which, due to the heterogeneity of tumors, may be required to accurately detect ER␣ mutations to determine realistic mutation rates. Although the rates of mutations are low in the primary tumor and increased in metastases, many of the single mutations identified to date have been demonstrated to influence breast cancer cell behavior.
Mutations that do not affect ER␣ functionality.
Some of the ER␣ point mutations do not demonstrate any observable phenotype different from that of wild-type ER␣. For instance, ER␣ S47T and K531E mutations identified from metastatic breast cancer specimens were analyzed for their ability to transactivate four different ERE reporter constructs in HeLa and MDA-MB-231 breast cancer cells (272) . The transactivation profiles of these two mutants did not differ from the transactivation status of the wild-type ER␣. Roodi et al. (271) have also identified two single mutations from an individual patient with a breast cancer metastasis. These two mutations, ER␣ N69K in the AF-1 transactivation domain and ER␣ M396V in the ligand binding domain, were identified from a tumor that was clinically ER-negative (271) . A missense mutation in the ER␣ D domain was identified as a leucine to proline substitution at amino acid 296 (274) . An ER␣ E352V mutation was also identified in a breast cancer patient who responded to adjuvant tamoxifen therapy (263) . Although these later mutations do not observably alter ER␣ functionality, many mutations have been identified that do dramatically affect the regulation of wild-type ER␣ and will be discussed next.
ER␣ A86V.
One of the first naturally occurring missense mutations identified in breast cancer specimens was ER␣ A86V (275, 276) . This mutation was found to be present in a subset of patients originally identified with a silent mutation at nucleotide 261 (275) . This combination of a silent mutation and a missense mutation has been found to be associated with several distinct phenotypes. First, women expressing this variant allele are significantly taller (277) , and ERpositive breast cancer patients have an elevated risk of spontaneous abortions if this double mutation is present (278) . Additionally, ER-positive breast tumors expressing this allele tend to have lower levels of ER protein when compared with tumors expressing wild-type ER␣ (275) . These data all demonstrate that a single mutation in ER␣ can have profound biological effects. It will prove useful when these studies are expanded to larger patient populations.
Because ER-positive tumors expressing this variant allele demonstrated reduced ER protein levels, Schmutzler et al. (279) hypothesized that it may be one mechanism leading to ER-negative tumors. To test this hypothesis, they examined genomic DNA, but found an approximately equal distribution of this variant allele (279) . In total, of the tissue samples from 483 women that were analyzed, 59 were found to carry this variant allele (279) . Additionally, blood samples from healthy women expressed the variant allele 9.5% (279) of the time. Interestingly, all carriers were heterozygous, suggesting that homozygous expression of this variant allele may not be viable. However, through power calculations, these authors determined that at least 960 samples would have to be tested to determine whether indeed the A86V homozygous cell is not viable.
ER␣ K303R.
Our group has identified a K303R somatic mutation at the border of the hinge and hormone binding domains of ER␣ in 34% of hyperplastic breast lesions (273) . Additionally, we have detected this same mutation in the majority of primary breast cancers (our unpublished results). In contrast to our findings in samples from the United States, Zhang et al. (280) were unable to find this mutation in a cohort of breast cancer samples from Japanese women. The reason for this ethnic difference is currently under investigation. Because this mutation is present only in tumor samples, and not in normal tissues, it may have an important role in tumor progression.
To examine a potential role for this mutation in tumor progression, MCF-7 cells with enforced expression of K303R ER␣ were analyzed. Both the wild-type and the K303R ER␣ mutant receptors have similar binding affinities for estrogen and tamoxifen (273) . Although these receptors have similar binding affinities, cells expressing the mutant receptor responded to 10 Ϫ12 m estrogen as well as they responded to 10 Ϫ9 m estrogen in an in vitro growth assay. MCF-7 cells expressing the wild-type receptor had a doubling time of 2.2 d and 1.3 d when grown in 10 Ϫ12 and 10 Ϫ9 m estrogen, respectively (273) . In contrast, cells expressing the mutant receptor had a doubling time of 1.3 d, regardless of whether the cells were grown in 10 Ϫ12 or 10 Ϫ9 m estrogen (273) . Because the estrogen binding affinities were identical, the binding of the ER␣ coactivator transcriptional intermediary factor 2 (TIF2) was analyzed. In vitro binding experiments revealed increased ER␣ association with transcriptional intermediary factor 2 at low levels of hormone, suggesting one potential mechanism for the observed increased sensitivity to estrogen (273) . We hypothesize that the K303R ER␣ mutation reduces the concentration of hormone required for the formation of the coactivator:ER␣ hydrophobic groove binding surface (131, 273) . Lysine at amino acid 303 has also been identified as a major acetylation site within ER␣ (281) . ER␣ acetylation was shown to modulate the response to ligand and may, in part, be a component of the mechanism leading to the increased estrogen hypersensitivity associated with this mutant receptor (281) . These data demonstrate that the K303R ER␣ mutation has acquired the ability to respond to much lower concentrations of estrogen, e.g., a gain of function mutation. Because the hypersensitive mutation has been found in a large percentage of primary tumor samples, we are currently examining its clinical role as a prognostic biomarker.
ER␣ 437Stop
The 437Stop mutation results from the deletion of a nucleotide in codon 432 leading to a frameshift and the introduction of a stop codon at residue 437 (263) . This mutation was first identified in a patient that had relapsed while on tamoxifen (263) . Interestingly, this mutation was found only in the metastatic lesion and not in the primary tumor, suggesting a role in tamoxifen resistance and/or metastatic spread (263) . Furthermore, Graham et al. (282) have identified an ER␣ 417Stop mutation in the tamoxifen-resistant T47D CO cell line. These two mutants suggest that loss of the ligand binding domain could be one mechanism, albeit infrequently, of acquired tamoxifen resistance. However, there have been no reports of these truncated proteins in vivo in tamoxifen-treated patients.
ER␣ Y537N/Y537S.
Before identifying Y537 as a site of natural mutation in breast cancer, much work had already been done with mutations at this site, demonstrating that this tyrosine is an important phosphorylation site with potential roles in regulating ligand binding, homodimerization, and transactivation of ER␣. These experiments, as well as additional Y537 experimental mutations are discussed in Section V.G. dealing with experimental mutations. Because of this earlier work, it was very exciting when Kohler et al. (283) identified a Y537S mutation in endometrial cancer and we found the Y537N mutation in an ER-negative metastatic breast cancer patient (272) . Because many publications have analyzed the Y537S mutation in conjunction with other Y537 mutants, the in vitro analysis of the Y537S mutation will be further discussed in Section V.G. dealing with experimental mutations. Transactivation analysis of the Y537N mutation was analyzed in both HeLa and MDA-MB-231 breast cancer cells utilizing four different ER-responsive promoter constructs: vitellogenin, pS2, cathepsin D, and lactoferrin (272) . It was demonstrated that, in the absence of estrogen, the Y537N mutant exhibited 5-to 20-fold higher levels of transactivation (vs. wild-type ER␣). Because this tyrosine residue is an important ER␣ phosphorylation site, a mutation at this site may allow ER␣ to escape phosphorylation-mediated controls (272, 284 -286) and provide a cell with a potential selective tumorigenic advantage. Because only a relatively few metastatic tumors have been examined for mutations at Y537, its frequency may be underappreciated.
ER␣ silent mutations.
In addition to the numerous nonsense and missense mutations that have been found in ER␣, several silent mutations have also been identified. These mutations do not alter the protein sequence, so they would not be predicted to significantly affect ER function. In fact, the majority of polymorphisms identified do not have an observable phenotype associated with them, regardless of the tissue of origin (263, 271, 287) . Although the ER␣ codon 10 polymorphism has been found in numerous normal and diseased tissues, it is not commonly associated with the diseased state (221, 283, 288, 289) . However, two other silent mutations, one in codon 87 and one in codon 325, have been reported to be associated with distinct phenotypes. The BstU1 restriction fragment length polymorphism (RFLP) is caused by a silent mutation in codon 87 (275) . This mutation was subsequently found to be linked with the A86V missense mutation, and it is associated with spontaneous abortions and reduced ER levels in breast cancer patients with ER-positive tumors, as discussed above. Multiple studies have demonstrated a correlation between a silent mutation at codon 325 and breast cancer risk (271, 290, 291) . Additionally, this mutation has been associated with low femoral neck bone mineral density (BMD), but not lumbar spine BMD (292) . Unfortunately, all of the correlative studies have involved a small number of patients. Although these silent mutations do not directly affect the protein sequence, they may indirectly affect protein function through alterations in RNA turnover rates, such as RNA half-life, and/or protein translation, hence indirectly altering total ER␣ protein levels. Thus, the exact mechanism of how these silent mutations affect ER protein function and their clinical significance remains to be elucidated.
F. Natural mutations conclusions
Mutations within ER␣ have been found in a number of different diseases, and it is interesting to note that many of these mutations were identified in breast cancer patients that were clinically classified as ER-negative. The ligand binding assay is the most common technique for determining tumor ER status and might not be efficient in detecting ERs with an altered ligand binding capacity or reduced protein levels; antibodies used for immunohistochemical studies may also suffer from these same limitations. Additional functional analysis of the mutations identified in patients will help to determine whether they indeed play a role in breast cancer progression and/or resistance to therapeutic treatment, or just represent errors without functional clinical meaning.
G. Experimental mutations
Many laboratories have used experimental mutagenesis techniques to identify the important functional amino acids in ER␣. Mutations have been introduced into the human ER␣ cDNA, resulting in well over 100 point mutations along the amino acid sequence of human ER␣ (outlined in Table 3 ). Many of these were made and screened for activating mutations, and thus a large number do not affect the protein function analyzed in the corresponding references. Although many of these mutations are listed as "no change" in function, this is not intended to imply that other, as yet unanalyzed, functions of these mutant ERs will not be altered. Several of these mutations have been extensively studied and reveal important aspects of ER␣ structure-function relationships, and they will be discussed in more detail. In addition to the single point mutations discussed in this paper, a number of proteins containing double and triple point mutations have been made and will be discussed briefly herein. Double and triple mutations within the DNA-binding domain generally demonstrated lost or reduced transactivation induced by estrogen and tamoxifen (293) (294) (295) (296) . In contrast, replacing the lysines at amino acids 302 and 303, within the hinge region, with arginine, glutamine, or alanine resulted in increased estrogen-induced transactivation (281) . A number of studies have reported double and triple mutations within the ligand-binding domain of ER␣ and generally result in decreased estrogen binding affinity and reduced estrogen induced transactivation (297) (298) (299) (300) (301) (302) (303) . Additionally, mutations within the ligand binding domain have also been shown to eliminate or reduce the agonist activity of tamoxifen and raloxifene (77, 124, 294, 304, 305) . Although a detailed discussion of ER␣ containing double and triple point mutations would undoubtedly be interesting and informative, it is beyond the scope of this paper.
ER␣ serine 118.
Because of the location of serine 118 within the ER␣ ligand-independent transactivation AF-1 domain, many groups have sought to determine the effects of phosphorylation at serine 118 on ER␣-induced transcriptional activation. S118 is a major ER␣ phosphorylation site that can be induced by estrogens, antiestrogens such as tamoxifen, and growth factors such as the EGF and IGF (105, 106, 306 -309). Experiments using pharmacological inhibitors have demonstrated that phosphorylation of S118 is dependent upon signaling through the Ras-MAPK pathway (105, 106, 306). Furthermore, Chen et al. (309) have demonstrated that the MAPKs ERK1/2 phosphorylate S118 in an estrogen-independent manner. Additionally, cyclin-dependent kinase (CDK)7, but not cyclin A-CDK2, has been shown to phosphorylate S118 in a ligand-dependent manner (309, 310) . A number of different growth factors have been demonstrated to induce phosphorylation of S118, and many of these factors are known to be involved in proliferation, cell-cycle regulation, and survival.
Mutational analysis has demonstrated that S118 is required for the complete transcriptional activity of ER␣ (105, 106, 308, 311, 312). Although mutation of serine 118 to alanine resulted in reduced transactivation, no change in estrogen binding affinity or ERE binding affinity was found (312) . EGF-induced transactivation of ER␣ is dependent on S118, but phosphorylation of S118 is not sufficient for transactivation (105). Furthermore, Karas et al. (306) examined differences in ER␣ signaling in human saphenous vein smooth muscle cells, pulmonary vein endothelial cells (PVECs) and COS-1 cells, and found that although MAPK-induced phosphorylation of S118 activates ER␣ transcription in nonvascular cells, mutation of S118 did not affect ER␣ transactivation in PVECs. Additionally, S118A altered ER␣ phosphorylation patterns in COS-1 and Sf9 cells but not HeLa cells, indicating some cell-type-specific effects on ER␣ posttranslational phosphorylation (312) . Collectively, these data suggest an important role for S118 phosphorylation in ER␣ transactivation; however, ER␣ S118 may also function in a cell-type-specific manner. The role of S118 in nuclear localization of ER␣ has been examined, and mutations at this site demonstrate this residue to be important for estrogen-independent nuclear localization of ER␣ (313) . In contrast, this residue has not been shown to be involved in estrogen-stimulated nuclear localization (313) . Additionally, constitutive activation of MAPK signaling results in the nuclear localization of ER␣, suggesting that phosphorylation of S118 is important for growth factormediated nuclear localization of ER␣ (313).
ER␣ aspartate 351.
A naturally occurring mutation in the ligand binding domain was discovered in the tamoxifenresistant MCF7/MT2 xenografted tumor line (314, 315) . Of note, the D351Y mutation was the primary form of ER identified in this particular tumor (314, 315) . Although this mutation was identified in only one of four tamoxifen-resistant xenografted tumor lines and has yet to be reported in human breast tumors, it has been the subject of much research and has revealed details about ER␣ structure-function relationships. The conversion of aspartate to tyrosine or glutamate results in a receptor that exhibits an estrogenic response to many antiestrogens, including raloxifene, EM652, GW7604, keoxifene, and tamoxifen (305, 316 -324) . Interestingly, the effects of the pure antiestrogen Faslodex (ICI 182,780) are unaffected by mutating this site to tyrosine (319, 322, 323) . Experimental mutagenesis of D351 to glycine, valine, or phenylalanine does not result in a receptor that responds to antiestrogens in an agonistic manner, demonstrating that only specific mutations result in activity inversion mutants (298, 321, 325) . These in vitro studies, combined with x-ray crystallography studies, have shown that D351 is critical for the interaction with the antiestrogenic side chains of SERMs (124, 131, 316, 320) . Liu et al. (316) tested whether the SERM side chain neutralizes the negative charge of aspartate, or whether "shielding" the negative charge is the mechanism responsible for the activity inversion mutants. Through the use of various mutants and R1/h (a raloxifene derivative unable to neutralize the negative charge of aspartate), Liu et al. demonstrated that the raloxifene side chain both shields and neutralizes the negative charge at D351 (316) . The estrogenic response of the D351Y mutant to antiestrogens requires the AF-1 domain because mutants with a deleted AF-1 domain lose the ability to increase ER transactivation in response to the antiestrogens tamoxifen and raloxifene (305, 326) . Although the AF-2 domain is not required, D351Y mutants possessing intact AF-1 and AF-2 domains produce a synergistic estrogenic response to antiestrogens (305, 326) . Furthermore, the ER␣ D351Y mutant shows reduced interactions with the corepressors NCoR and SMRT (324) . Collectively, these data demonstrate an important role for D351 in the ER␣ response elicited by SERMs.
ER␣ glycine 400.
A glycine residue at amino acid 400 also lies within the ligand binding domain of ER␣. However, in contrast to D351Y, mutation of G400 does not result in a receptor that exhibits an agonistic response to keoxifene (320, 327) . However, G400V has been demonstrated to convert tamoxifen from a partial agonist into a full agonist (328) . Upon examination of binding affinity, it was found that the G400V mutant has 10-to 100-fold lower affinity for both estrogen and antiestrogens (327, 329) . However, estrogen, albeit at higher concentrations, was able to activate both the wild-type and the mutant receptors to similar levels (330) .
Collectively, these data demonstrate that the G400 mutation alters ligand binding affinity, but not ER␣-induced transcriptional activity. Although wild-type ER␣ demonstrates low levels of ERE DNA binding in the absence of estrogen, the G400V mutant is devoid of ERE binding and transactivation in the absence of estrogen (325, 331) . Metzger et al. (332) studied the effects of heat on the ability of ER␣ to bind on the ERE. It was found that although heat inactivated binding of both wild-type ER␣ and the G400V mutant ER, the ERE binding capacity of the mutant was reduced more quickly compared with wild-type ER␣ (332) . This effect was independent of estrogen, tamoxifen, or ICI 164,384 (332) . Analysis of the ability of dopamine to activate ER␣ demonstrated that dopamine induced transcriptional activity only in wild-type ER␣, and not of the G400 mutated ER␣. Additionally, dopamine in combination with estrogen induced a synergistic increase in transcriptional activity in the mutated ER, whereas the wild-type ER only demonstrated an additive increase in transcriptional activity (330) , thus suggesting a cooperative mechanism of ER␣ activation. These data also demonstrate that mutation of glycine at amino acid 400 within the ligand binding domain results in an ER␣ with a reduced affinity for estrogen leading to reduced ERE binding and transactivation.
ER␣ cysteine 530.
Amino acid residues 515-535 have been suggested to play a critical role in ligand binding (333) . The cysteine at position 530 has received considerable attention and study. Although C530A has been the most commonly made in vitro mutation, Neff et al. (334) have identified C530P, C530G, and C530W as the most informative mutations at this site. Despite having an unchanged estrogen binding affinity, these mutations were shown to have reduced estrogen-mediated transcription as well as ERE binding activity (334) . In contrast, the C530A mutant showed similar estrogen and ERE binding affinities and estrogeninduced transcription (334 -336) . Additionally, C530A did not result in differential effects of hexesterol, P1496, or tamoxifen (337) . Because estrogen and tamoxifen bind in a noncovalent, reversible manner, the important role of this cysteine is most notably seen when covalently binding ligands are used. C530 has been identified as a covalent attachment site for 17-␣-(haloacetamidoalkyl) estradiols, 11␤-[(aziridinylalkoxy)phenyl]estradiols, kenostrol aziridine, and tamoxifen aziridine (335, 338, 339) . Mutation of this cysteine did not alter binding of reversible ligands but showed a 10-fold reduction in kenostrol aziridine and tamoxifen aziridine binding (335) . Furthermore, the covalently attaching 11␤-[(aziridinylalkoxy)phenyl]estradiol did not affect the ability of estrogen to bind in the ER containing the C530A mutation (338) . These data suggest that C530 is a critical residue for covalently attaching ligands; thus, new antiestrogenic therapeutic strategies targeting this residue may hold future promise for the treatment of breast cancer.
C530 lies outside the nuclear localization signal, and consequently, it would not be expected to impact nuclear localization; however, Neff et al. (334) have also demonstrated that C530 may play a role in nuclear translocation. Two mutants, C530S and C530P, demonstrated high levels of cytoplasmic ER␣ in the absence of estrogen, whereas stimulation with estrogen results in nuclear translocation of these two mutant receptors (337) . The wild-type receptor, along with eight other mutants, demonstrated primarily nuclear localization, regardless of the presence or absence of estrogen (337) . These data suggest that specific mutations outside the nuclear localization signal can still significantly affect the subcellular localization of the ER.
ER␣ tyrosine 537.
Because tyrosine 537 to asparagine was identified as a naturally occurring, constitutively active mutation (272), Y537 has been an informative site for in vitro mutation analysis. In addition to ER␣ Y537N, alanine and serine also result in a constitutively active receptor (115, 325, 340) . Estrogen binding affinities were measured for several of the mutants, with phenylalanine and serine demonstrating similar binding affinities as wild-type ER␣, but a glutamic acid substitution exhibited a 10-fold reduction in estrogen binding affinity (341) . Interestingly, all of these mutated receptors retain the ability to respond to antiestrogens by inhibiting both basal and estrogen-induced ER␣ transcriptional activity (115, 342). When the crystal structure was solved, Y537 was found to be the amino-cap residue of helix 12 (343) . Helix 12 has been shown to stabilize ligand binding and to be important for creating the agonist bound conformation allowing ER␣ to actively recruit coactivators (124, 125) . Y537 and the amino-cap of helix 12 thus play important roles in the activation and regulation of ER␣ signaling.
A number of studies have demonstrated that tyrosine 537, the major tyrosine phosphorylation site in ER␣ (344), also plays a critical role in the dimerization and DNA binding of ER␣. Treatment of wild-type ER␣ with the tyrosine-specific phosphatase, protein tyrosine phosphatase 1B (PTP1B), significantly reduced the ability of ER␣ to dimerize and bind DNA in a dose-dependent manner (345) . This reduced ability of dephosphorylated ER to dimerize and bind DNA could be restored by pretreating ER␣ with the c-Src family kinases pp60c-src or p56lck (286, 345) . Additionally, dimerization of wild-type ER␣ can be blocked by the addition of free phosphotyrosine or a phosphotyrosyl peptide, indicating that the dimerization domain of one ER␣ binds to the phosphorylated tyrosine of an adjacent receptor (285) . Furthermore, using a bivalent antihuman ER␣ antibody, inactive (e.g., unphosphorylated) ER␣ monomers can be induced to dimerize and bind to DNA (345) . These data would suggest that phosphorylation of Y537 is critical to ER␣ activation; however, more recent studies have demonstrated that phosphorylation of Y537 is not required for hormone binding or transactivation (344) . Y537 forms a hydrogen bond with N348 upon ligand binding, and this newly formed hydrogen bond stabilizes helix 12 in the "closed" pocket formation (340) . Mutation of Y537 to phenylalanine, but not serine or glutamic acid, abolishes this hydrogen bond (124, 131, 341) . This "lost" hydrogen bond correlates with monophasic estrogen dissociation kinetics, suggesting an inability of ER␣ to dimerize (341, 346) . In contrast, wild-type ER␣ and Y537S or Y537E demonstrate biphasic dissociation kinetics (341). Yudt et al. (346) have suggested that the monophasic dissociation kinetics are due to the lost hydrogen bond allowing an open or loose pocket conformation, regardless of the presence or absence of ligand, rather than an inhibition of ER dimerization. Although Y537 undoubtedly plays a critical role in ER␣ activation, its exact mechanism of action remains unclear.
6. ER␣ leucine 540. Mutation of leucine to glutamine at amino acid 540 has been generated by chemical mutagenesis (347) . This mutation exhibits reduced basal transcriptional activity and has lost the ability to respond to estrogen, although it can bind estrogen with normal affinity (298, 347, 348) . Similar to the mutations described at amino acid 351, L540Q has increased transcriptional activity in response to many antiestrogens, including ICI 164,384, RU54876, and tamoxifen (348, 349) . More importantly, L540Q can act as a dominantnegative receptor by inhibiting the activity of wild-type receptor by as much as 75% (347) . This dominant-negative receptor has been used to reduce established ER-positive T47D xenografted tumors when animals were treated with adenovirus containing the L540Q mutant ER (350) . Furthermore, expression of L540Q resulted in increased levels of Bax protein and elevated p38 MAPK phosphorylation leading to cellular apoptosis (350) . It has been hypothesized that L540 may play a role in regulating ER ligand recognition or transcriptional activation.
L540Q can inhibit wild-type ER␣ through a dominantnegative manner; thus, multiple groups have sought to determine the exact ER␣ regions important for this dominantnegative effect. Montano et al. (348) have demonstrated that the ER␣ A/B domain is important for the estrogenic response of the L540Q mutant to antiestrogens. Additionally, deleting the A/B domain in the L540Q mutant resulted in a receptor that no longer acts as a dominant-negative; these double mutants still retain the ability to dimerize with wild-type ER␣ but are unable to inhibit its activity (349, 351) . The introduction of a dimerization-deficient mutation (L507R) into this dominant-negative receptor abrogates the ability of the L540Q mutation to inhibit wild-type ER␣ (351) . These data support the hypothesis that the dominant negative effect of L540Q involves the AF-1 transactivation domain and that dimerization of the mutant to wild-type receptor is critical for this effect.
H. ER␣ experimental mutations summary
The ability to target specific regions of ER␣ by site-directed mutational analysis has allowed researchers to tease apart the various mechanisms of ER␣ action, including ligand interactions, transactivational requirements, and numerous corepressor and coactivator interactions. Future studies such as these will undoubtedly aid in developing ER␣-specific therapies for the treatment of human breast cancer.
VI. Splicing and Genetic Alterations of ER␤
A. Alternative exons in the 5ЈUTR
Although many alternatively spliced exons have been described in the 5Ј UTR of ER␣, only two have been described for ER␤. Exons ON and OK have been demonstrated to regulate ER␤ gene expression (352) . Whereas exon ON is found in a wide range of tissues including the spermatozoa, uterine endometrium, uterine myometrium, and peripheral leukocytes, exon OK is predominantly found in spermatozoa (352) . It is interesting to note that the sequence of exon OK was found to be identical to the 5Ј UTR of ER␤cx, which can function as a dominant-negative receptor for ER␣, to be discussed in the next section (352, 353) . These data suggest that exon OK may play a role in more than just tissue-specific expression of ER␤ or may directly affect signaling of both ER␣ and ER␤.
B. Natural mRNA splice variants
By far, the vast majority of identified alterations within the ER␤ sequence are differentially spliced variants ( Table 4) . As with ER␣ splice variants, ER␤ splice variants have been found in a number of different normal and diseased tissues. ER␤ was identified much later than ER␣, hence much less is known with respect to its splice variants, sequence mutations, and the protein functions of these isoforms. Although significantly fewer ER␤ splice variants have been identified to date, their number is growing rapidly.
1. ER␤2/ER␤cx. ER␤cx, also known as ER␤2, is one of the few splice variants that has been demonstrated to have potential clinical relevance at both the mRNA and protein levels. This variant is generated by replacing the last 61 amino acids of ER␤ with 26 novel amino acids, and it lacks amino acids important for ligand binding and AF-2 function (353). The resulting translated protein does not respond to ligand, exhibits lost or reduced DNA binding abilities, and demonstrates dose-dependent dominant-negative activity, preferentially against ER␣ (26, [353] [354] [355] . Analysis of ER␤cx expression in the endometrium has shown that ER␤cx levels fluctuate during the menstrual cycle (179) . Protein levels were also reduced in gland cells in the functional layer, but not in the basal layer of the endometrium (179) . The fluctuation of ER␤cx protein levels during the menstrual cycle suggests a physiological role for this protein in normal tissues. Analysis of ER␤cx in one study of normal breast and breast cancer specimens has revealed that approximately 54% of breast cancers express ER␤cx variant, whereas only 9% of normal breast tissue express this variant (203) . Additionally, as ER␤cx has dominant-negative activity against ER␣, Saji et al. (356) examined ER␣-positive tumor foci for the coexpression of ER␤cx and PR. These studies revealed a correlation between ER␤cx expression and the lack of PR expression (356) . However, when this study was enlarged to the entire tumor, ER␤cx expression did not significantly correlate with negative PR status (356) . This same research group examined ER␤cx expression and tamoxifen resistance and found that ER␣-positive tumors with ER␤cx expression and negative PR status exhibited a poor response to tamoxifen, whereas tumors lacking ER␤cx expression responded well to tamoxifen (357) . The significance of this observation is not understood at present, because it is known that ER␣-positive/PR-negative tumors do not respond as well to tamoxifen. Analysis of ER␤cx expression in breast tissues has thus suggested some correlation with tamoxifen resistance, but this observation needs to be confirmed in large studies.
ER␤ exon 2 deletion (⌬2).
Deletion of exon 2 has been found to be the most common ER␤ splice site, and it is frequently associated with deletion of exons 5 or 6 (358) . The loss of exon 2 results in a premature termination codon leading to a predicted carboxy-truncated protein (358) . Although this is the most common splice variant, no significant differences in expression between breast cancer or matched normal breast from a distant site have been reported (359) . Thus, preliminary data suggest that the exon 2 splice variant may not play a significant role in breast tumorigenesis, which may limit its impact, if any, in breast cancer.
ER␤ exon 3 deletion (⌬3).
The ⌬3 variant, originally identified in normal ovarian tissue, does not result in a disruption of the ER␤ open reading frame (358) . However, exon 3 does encode the second zinc finger in the DNA binding domain (358) , and this zinc finger has been demonstrated to be required for ER␤ cross-talk with Stat5b (360) . Although this mutation has not been identified in breast cancer, it may play a role in differential interactions with other transcription factors and is worthy of future study.
ER␤ exon 4 deletion (⌬4).
Similar to ⌬3, loss of only ER␤ exon 4 does not result in a disruption of the open reading frame (358) . However, this splice variant does lack the nuclear localization signal and appears to be localized to the cytoplasmic spaces (358) . Although ⌬4 has been identified in breast cancer, no significant differences have been observed between normal breast and breast cancer (359) . The role of ⌬4 in breast tumorigenesis is currently unknown.
ER␤ exon 5 deletion (⌬5).
Because much work has been done analyzing the role of the ER␣ ⌬5 isoform, it is not surprising that ER␤ ⌬5 is one of the most studied ER␤ splice variants. This variant also lacks part of the hormone binding domain (358, 361) . The resulting protein is properly localized to the nucleus, and does not have any differential effects on basal activation of ER␤ (270) . However, ⌬5 acts as a dominantnegative receptor for estrogen-induced transactivation of both ER␣ and ER␤ in a dose-dependent manner (270, 355) . Ten-fold more ER␤ ⌬5 was required to inhibit 80% of the estrogen-induced activity of ER␣ or ER␤ (270) . It has been suggested that expression of ⌬5 could impair the normal functions of both ERs, potentially contributing to the genesis of estrogen-independent breast cancer.
ER␤ ⌬5 has been found in a number of different tissues including ovary, uterus, normal breast, and breast cancer (358, 362) . One study found ⌬5 in normal breast, but not in breast cancer (358) . However, a later study by the same group found elevated levels of the ⌬5 variant to be associated with high tumor grade and postmenopausal status; grade 3 breast cancer expressed higher levels of ER␤ ⌬5, whereas grade 2 tumors exhibited reduced expression when compared with matched normal breast (359) . Interestingly, this variant was also found in the ER␣-negative breast cancer cell line, MDA-MB-231 (361) . ER␤ ⌬5 has the potential to play a role in breast tumorigenesis, but additional studies with larger numbers of clinical samples examining ⌬5 at the protein level are needed to ascertain a definitive role. Ubiquitous expression in all tissues tested, highest in placenta, spleen, leukocytes, testis
ER␤ exon 6 deletion (⌬6).
In contrast to ER␣, the ER␤ exon 6 is commonly deleted and results in a truncated translation product (358) . Although this variant was found at slightly lower levels in breast cancer compared with normal breast, the differences were not statistically significant (359) . This difference was also not correlated with histological type, grade, ER␣ or PR status, menopause, or nodal status (359) . Therefore, although the ER␤ exon 6 is commonly deleted in the breast, it does not appear to play a significant role in breast tumorigenesis.
ER␤ exon 7 deletion (⌬7)
. ER␣ ⌬7 is the most frequently observed variant in human breast cancer; however, deletion of exon 7 is relatively rare in ER␤. Two separate studies have failed to detect ER␤ splice variants containing a deletion of this exon (358, 359) . The lack of ER␤ ⌬7 variant expression is similar to ER␣ ⌬6 expression, suggesting that both exon 6 in ER␣ and exon 7 in ER␤ may play vital roles in ER function.
C. mRNA splice variants summary
ER␤ was discovered more than three decades after ER␣, and therefore much less is known about its functional interactions. The recent identification of multiple ER␤ splice variants may help to elucidate the role of ER␤ and its variants in breast cancer. It is interesting to note that ⌬6 is a rare splice variant in ER␣, whereas ER␤ ⌬6 is fairly common. Additionally, ER␣ ⌬7 is a fairly common-occurring splice variant, but deletion of exon 7 in ER␤ is virtually nonexistent. Exons 6 and 7 in both ER␣ and ER␤ encode portions of the ligand binding domain and the AF-2 transactivation domain. Why exon 6 in ER␣ and exon 7 in ER␤ are infrequently spliced remains to be elucidated. These two exons may be important for the stabilization of ER mRNAs; their deletion may lead to degradation and may be associated with our inability to find these deletion variants. These data suggest an as yet unknown important role for this region in ER function. Deletion of exon 5 in both ER␣ and ER␤ has proven to be common and potentially clinically relevant, but in contrasting ways. ER␣ ⌬5 is a constitutively active receptor, whereas ER␤ ⌬5 can act as a dominant-negative isoform of both ER␣ and ER␤. ER␣ expression is a good prognostic indicator for clinical outcome; thus, a naturally occurring dominantnegative ER␤ could suppress the beneficial effects of ER␣ expression, thereby indirectly contributing to tumor progression. Additionally, alternatively spliced variants have been shown to lead to important effects on ER function, such as differential interactions with transcription factors and altered nuclear localization.
D. Natural point mutations identified in human tissue samples
Although numerous splice variants of ER␤ have been identified, relatively few point mutations have been reported. A G250S mutation was identified in obese male children, and this same study identified several silent mutations in both underweight and obese children (363) . These include the base-pair changes, 1082G to A, 1421G to C, and 1730G to A, but these polymorphisms were not associated with any of the phenotypes analyzed (363) . ER␣ has been associated with BMD; thus, there have been searches for ER␤ mutations also in postmenopausal women with osteoporosis (364) . A silent mutation in codon 328G to A was identified and demonstrated to lead to an RsaI RFLP (364) . This RFLP was then used to screen a larger cohort of patients to demonstrate that the silent mutation at codon 328 was not significantly associated with BMD (364) . In summary, the number of point mutations identified within the ER␤ sequence is few, and thus, their clinical relevance remains to be discovered.
E. Experimental point mutations
Analysis of ER␤ function through the use of experimental mutations has been very limited to date. One study by Bjornstrom and Sjoberg (360) made several single and double point mutations in the zinc finger domain of ER␤ to identify key residues involved in DNA binding and transactivation, and these mutations abrogated ER␤-induced reporter activity. These mutations include R207A/K208A, E167A/G168A, C201A/C204A, C149A/C152A, and A187T (360) . Interestingly, S200E also abrogated ER␤ transactivation, but the S200A mutation had no effect on transactivation (360) . In addition, L206A, R207A/K208A, Y210A, and P186T mutations exhibited little effect on the activity of ER␤ (360) . Furthermore, analysis of ER␤ cross-talk with Stat5b or AP-1 indicated that disruption of the second zinc finger domain was important for signaling through Stat5b, but the first zinc finger was found to be irrelevant for Stat5b signaling (360) . In contrast, AP-1 signaling required both zinc finger structures for ER␤-induced AP-1 signaling (360) . Furthermore, the DNA binding ability of ER␤ was found to be inconsequential for estrogen-induced Stat5b or AP-1 activity (360) . In contrast to ER␣, relatively few point mutations in the ER␤ protein sequence have been discovered or experimentally constructed; thus, we are just beginning to elucidate potential ER␤ actions in the breast and to find functions that are distinct from ER␣.
F. ER␤ summary
To date, ER␤ point mutations have not provided much insight into the mechanism of action of ER␤, because relatively few naturally occurring point mutations have been identified and in vitro mutagenesis experiments with ER␤ are few. However, as was done with ER␣, future mutagenesis work will help to unravel the potential functions of ER␤ signaling in the normal breast and breast cancer.
VII. Discussion
Due to the normal function of the ERs in mammary gland development, it is not surprising that ER signaling has been implicated in breast cancer progression and metastasis. Many groups have identified naturally occurring mutations and splice variants with constitutive activity, even in the absence of estrogen. Additionally, a naturally occurring ER␣ mutation (K303R) has been identified which leads to a receptor that is able to induce proliferation in low levels of hormone. These alternate receptor forms could lead to uncontrolled proliferation, potentially providing a cell with a growth advantage. Additional mutants act as dominantnegatives and inhibit ER action. Interestingly, a number of these were identified in tamoxifen-resistant or clinically ER-negative tumors. Taken together, these data support dual roles for ER signaling in breast cancer: 1) uncontrolled ER signaling that can lead to increased cellular proliferation, or 2) ER signaling is required for normal growth controls, where a loss of ER signaling can lead to hormoneindependence, clinically ER-negative tumors, or a more aggressive phenotype.
In addition to the many splice variants and mutations reported to be expressed in breast cancer, the story may be even further complicated by direct heterodimerization between ER␣ and ER␤. It has been suggested that it is not the individual levels of ER␣ or ER␤, but the ratio of ER␣:ER␤ that may be most important. How might the ratios of ER␣:ER␤ be important? ER␤ usually exhibits weak ligand-independent transactivation; therefore, an ER␣/ER␤ heterodimer should theoretically have less ligand-independent (e.g., cAMP, dopamine, and growth factor-induced) transcriptional activity compared with ER␣/ER␣ homodimers. However, ER␤ retains normal ligand-dependent transcriptional activity; therefore, ER␣/ER␤ heterodimers could be activated by estrogen-dependent mechanisms to similar levels as ER␣ homodimers. Heterodimerization is a potential mechanism whereby the cell could limit the immediate response to nonestrogenic signals and, hence, restrain growth factor signaling through ER␣. In addition to the ratio of ER␣:ER␤, it has been suggested that splice variants may serve to regulate the pool of mRNA available to produce full-length protein, thereby controlling ER expression levels in a tissue-specific manner (365) . These data would imply that, although they do not regulate one another at the genetic level, they may regulate one another at the epigenetic level.
It is interesting to note that although a large number of splice variants have been reported, only a handful of mutations have been identified or studied from human patient samples. Furthermore, most of these single base-pair mutations have little or no observable effect on function. However, there may be multiple "hot spots" for spontaneous ER mutations. For instance, three separate ER␣ mutations have been found in the relatively short hinge region, and one of these mutations, K303R ER␣, has been found at a relatively high frequency in primary breast cancers (366) . The hormone binding domain comprises a large portion of the ER␣ protein; therefore, it is not surprising that many mutations would be found within this region. However, tyrosine 537 is the only amino acid that has been found mutated to two different amino acids. Because these mutations have been identified in breast cancer patient samples, they are the focus of intense research that has yielded valuable insights into potential mechanisms of hormone-independent signaling.
Experimental mutagenesis studies have also yielded significant insight into hormone action in the breast. These studies have determined critical residues for ligand binding, coregulator proteins, DNA binding, dimerization and activation states. These types of in vitro mutagenesis studies will undoubtedly aid in the development of newer, more effective pure antiestrogens. Additionally, it may be possible to modulate the activities of ER and potentially activate the antitu- 
